Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran

Khadijeh Ezoji[1,2], Mohsen Yaghoubi[3], Marzieh Nojomi[4], Sussan Mahmoody[5], Seyed Mohsen Zahraie[5], Maziar Moradi-Lakeh[4], Sedigheh R. Tabatabaei[6] and Abdollah Karimi[6]

[1]Social Determinants of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Islamic Republic of Iran. [2]Department of Community Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran. [3]School of Public Health, University of Saskatchewan, Saskatoon, Canada. [4]Preventive Medicine and Public Health Research Center, Department of Community Medicine, School of Medicine, Iran University of Medical Sciences, Tehran, Islamic Republic of Iran (Correspondence to Maziar Moradi-Lakeh: moradilakeh.m@iums.ac.ir). [5]Center for Communicable Disease Control, Ministry of Health and Medical Education, Tehran, Islamic Republic of Iran. [6]Pediatric Infections Research Center, Research Institute for Child Health, Shahid Beheshti University of Medical Sciences, Tehran, Islamic Republic of Iran (Correspondence to Sedigheh R. Tabatabaei: srt.tabatabaei@gmail.com).

Abstract

Background: Pneumococcal disease caused by Streptococcus pneumoniae results in considerable mortality and morbidity. Pneumococcal conjugate vaccines (PCV), such as PCV-13, can prevent invasive pneumococcal disease and avoid disability and death. The cost of introducing PCV-13 in childhood immunization schedules should be assessed against the cost of pneumococcal diseases for each community.

Aims: This study aimed to evaluate the cost–effectiveness of introducing PCV-13 in the national immunization programme for children under 5 years in the Islamic Republic of Iran.

Methods: The TRIVAC decision support model was used to estimate total costs of introducing PCV-13 and the disability-adjusted life years (DALYs) averted. The main pneumococcal diseases were considered—pneumonia, meningitis, acute otitis media, and non-pneumonia, non-meningitis infections—in terms of hospital admissions, outpatient visits and deaths. Local data were used to estimate costs.

Results: Pneumococcal disease is estimated to affect 18 713 211 children under 5 years (519 412 pneumonia, 18 148 116 acute otitis media, 6884 meningitis, and 38 799 non-pneumonia, non-meningitis) in 10 years (2014–2023) without use of the vaccine. Introduction of PCV-13 would prevent 4 900 084 cases of pneumococcal disease (190 849 pneumonia, 4 692 450 acute otitis media, 2529 meningitis, and 14 256 non-pneumonia, non-meningitis). Pneumococcal infection would cause 287 950 hospital admissions and 29 399 deaths; vaccination could avert 105 802 hospital admissions and 9997 deaths. The incremental cost–effectiveness was estimated to be US$ 1890 and US$ 1538 per averted DALY for the government and society respectively.

Conclusion: According to WHO-recommended thresholds for interpreting cost–effectiveness, introduction of PCV-13 for children under 5 years in the Islamic Republic of Iran would be cost-effective.

Keywords: pneumococcal conjugate vaccine, children, cost–effectiveness, Iran

Citation: Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Mohsen-Zahraie S; Moradi-Lakeh M. et al. Cost–effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran. East Mediterr Health J. 2019;25(10):686–697. https://doi.org/10.26719/emhj.19.039

Received: 02/09/17; accepted: 19/04/18

Introduction

Streptococcus pneumoniae is a well-known invasive bacterium. Disease caused by *S. pneumoniae* (pneumococcal diseases) can result in death, especially in very young children. *S pneumoniae* causes about 11% (8–12%) of all deaths in children aged 1–59 months (*1*). The diseases range from non-invasive pneumococcal diseases (e.g. acute otitis media) to invasive pneumococcal diseases (e.g. meningitis and bacteraemia) that can be life-threatening (*2–5*). Invasive pneumococcal diseases kill over 500 000 children under 5 years old each year (*6*), and accounted for nearly 9% of deaths in children aged 1–59 months in 2008 in South America (*7*). Children in low-income and developing countries are particularly at risk of severe disease caused by S. pneumoniae (*6*). The cost of diseases caused by S. pneumoniae is reported to be one of the highest in terms of the use of health care resources (*6,8*). However, invasive pneumococcal diseases can be prevented by vaccination (*3,6*).

Among all serotypes of *S. pneumoniae*, only a few are invasive and the new pneumococcal conjugate vaccines (PCVs) protect against them (*6,9*). Of the most preventable serotypes, the PCV vaccines target either 10 serotypes (PCV-10) or 13 serotypes (PCV-13) (*9*).

The main advantage of a childhood vaccination programme against *S. pneumoniae* is that it saves lives by preventing *S. pneumoniae* infection and hence the adverse complications of pneumococcal diseases, and this counterbalances the costs of the programme (*5*). Vaccination of children under 5 years would also indirectly reduce the incidence of invasive pneumococcal diseases by reducing the rate of nasopharyngeal carriers of *S. pneumoniae* (*10–12*).

After running several clinical trials in different regions of the world, PCV-10 and PCV-13 have been introduced in the national vaccination programmes of more than 100 countries, including many low- and middle-income developing countries. These vaccines have been found to be cost-effective, especially in developing countries with limited health care resources (*3*,*8*,*9*), and can be safely administered at the same time as other vaccines without interference (*9*).

The pneumococcal vaccine is not part of the childhood immunization programme in the Islamic Republic of Iran. However, acute respiratory infection was the fourth leading cause of death in children under 5 years in the country in 2013 (13%), so there is a need to protect children from the diseases related to *S. pneumoniae* (*13*).

When introducing a new vaccine, there are almost always financial and programmatic limitations, and many criteria should be taken into account to make a final decision (*14*). Analysis of cost–effectiveness is a useful method to provide an overview of health care resources (*8*). In the case of PCVs, the benefits and costs of introducing the vaccine in the routine schedule should be weighed against the cost of invasive pneumococcal diseases in a particular community.

Therefore, this study aimed to determine the cost–effectiveness of introducing PCV-13 into the Iranian national immunization programme for children under 5 years.

Methods

TRIVAC decision support model

We used the TRIVAC decision support model (version 1.7) developed by the London School of Hygiene and Tropical Medicine in collaboration with the Pan American Health Organization (PAHO) and ProVac Initiative and the World Health Organization. It is a Microsoft Excel based static cohort model designed to facilitate cost–effectiveness analysis of vaccination programmes against Haemophilus influenzae type b, rotavirus or *S. pneumoniae* in low- and middle-income countries (*15*). We considered four main disease states resulting from *S. pneumoniae* infections: pneumonia, meningitis, acute otitis media and non-pneumonia, non-meningitis infections, and other diseases except sepsis) in terms of hospitalization (inpatient admission), outpatient visits and death.

The TRIVAC model requires the following data: demographic data, disease burden, local vaccine serotype distribution, vaccine efficacy, health service utilization, vaccination programme costs and health service costs (*6*). Based on the data entered, the model calculates the number of cases, deaths and sequelae of S. pneumoniae infection, as well as the associated costs in scenarios with and without vaccination. These data are then used to calculate the health impact [e.g. disability-adjusted life years (DALYs) averted], economic impact (e.g. net costs, incremental programme costs and treatment costs averted), cost–effectiveness (e.g. cost per death averted) and cost utility (e.g. cost per DALY averted) of the vaccination programme (*15*).

Demographic data

The number of live births was derived from the Iranian national organization for civil registration. We used estimates of the Institute for Health Metrics and Evaluation for infant, under-5 and neonatal mortality (*16*). We also used the United Nations Population Division database to extract estimates of current and future life expectancy in the Islamic Republic of Iran (*17*).

Disease burden

We used data of the Institute for Health Metrics and Evaluation for annual incidence of acute otitis media (Table 1) (*16*). For pneumococcal pneumonia, we used the incidence and case fatality rate of pneumococcal pneumonia estimated by Rudan et al. for the Islamic Republic of Iran in 2013 (*18*). The number of new episodes of pneumonia divided by the number of population (0–4 years) was estimated at 830 per 100 000.

No local data were available for pneumococcal meningitis, and non-pneumonia, non-meningitis infections, so data based on the study of O'Brien et al. were used (*1*).

Given the lack of national published data on meningitis sequelae, we used estimates from a recent global systematic review of the proportion of meningitis survivors with single (20.2%) or multiple (4.5%) major sequelae (*19*). Major sequelae include hearing loss and multiple impairments. Standard global burden of disease categories (cognitive deficit, bilateral hearing loss, motor deficit, seizures, visual impairment and hydrocephalus) were considered major sequelae (*19*).

The disability weights due to all-cause acute otitis media, pneumococcal pneumonia and pneumococcal meningitis were taken from the global burden of disease study 2016 (*20*). For pneumococcal non-pneumonia, non-meningitis infections, we used the disability weights of Griffiths, which were 0.24 for single pneumococcal sequelae and 0.63 for multiple pneumococcal sequelae (*21*).

The mean duration of disease was considered six days for acute otitis media and non-pneumonia, non-meningitis infections, and 10 days for pneumonia and meningitis based on local expert opinion.

Vaccine coverage and efficacy

The vaccine (PCV-13) is available as a one-dose vial, Prevnar13 (Pfizer, United States of America). A vaccination schedule of three primary doses (at 2, 4 and 6 months) was chosen for PCV13 based on WHO guideline and an advisory consultation with the Iranian Ministry of Health and Medical Education (Table 2).

Vaccine efficacy data were taken from reports of systematic reviews and meta-analyses from different sources (Table 3). For all-cause acute otitis media, full-dose efficacy data were based on Pavia et al. in 2009 (*23*). Full-dose vaccine efficacy against vaccine-type pneumococcal pneumonia, meningitis, and non-pneumonia, non-meningitis infection was derived from Lucero 2009 (*2*).

Serotype coverage

Based on a systematic evaluation of global serotype coverage, we assumed that 70% of pneumococcal acute otitis media, pneumonia, meningitis, and non-pneumonia, non-meningitis infection were covered by the vaccine in the Islamic Republic of Iran (*25,26*).

Cost estimation

Vaccination programme costs

We used WHO guidelines to calculate the costs of introducing PCV-13 into the current national immunization programme (*27*). The price of each dose (US$ 20) was obtained from the local representative of the vaccine manufacturer (Pfizer). To estimate the incremental system cost per dose, we included the cost of the distribution system, cold chain, surveillance monitoring, training, maintenance, personnel expenses, and the facilities needed for this vaccination programme. The total annualized capital cost estimate was based on equipment prices and their useful life and an annualizing factor (Table 4).

Table 1 Estimated burden of pneumococcal diseases in the Islamic Republic of Iran used for the TRIVAC model

Variable	Estimate	Scenario		Source/s
		High	Low	
Annual incidence per 100 000, ages 1–59 months				
All-cause acute otitis media	29 000	35 000	24 000	Institute for Health Metrics and Evaluation (*16*)
Pneumococcal pneumonia	830	630	412	Rudan et al. (*18*)
Pneumococcal meningitis	11	15	9	O'Brien et al. (*1*)
Pneumococcal NPNM	62	89	55	O'Brien et al. (*1*)
Case fatality ratios, ages 1–59 months (%)				
Pneumococcal pneumonia	2.6	3.2	1.6	Rudan et al. (*18*)
Pneumococcal meningitis	57	74	35	O'Brien et al. (*1*)
Pneumococcal NPNM	44	57	27	O'Brien et al. (*1*)
Sequelae in pneumococcal meningitis survivors (%)				
Major sequelae (single)	20.2	20.2	20.2	Edmond et al. (*19*)
Major sequelae (multiple)	4.5	4.5	4.5	Edmond et al. (*19*)
Disability weight for DALY calculations (%)				
All-cause acute otitis media	2	0.5	4.5	GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (*20*)
Pneumococcal pneumonia	22.3	20	24.9	GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (*20*)
Pneumococcal meningitis	7.9	3.9	11.8	GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (*20*)
Pneumococcal NPNM	27.9	27.9	27.9	Assumption (TRIVAC)
Major sequelae (single)	21.0	21.0	24.0	Griffiths (*21*)
Major sequelae (multiple)	62.7	62.7	62.7	Griffiths (*21*)
Mean duration of illness (days)				
All-cause acute otitis media	6	10	4	Assumption (TRIVAC)
Pneumococcal pneumonia	10	21	7	Assumption (TRIVAC)
Pneumococcal meningitis	10	21	7	Assumption (TRIVAC)
Pneumococcal NPNM	6	10	4	Assumption (TRIVAC)
Age distribution of disease cases and deaths (%)				
< 3 m	9.4	9.4	9.4	Hortal et al. (*22*)
3–5 m	9.4	9.4	9.4	Hortal et al. (*22*)
6–8 m	9.8	9.8	9.8	Hortal et al. (*22*)
9–11 m	9.8	9.8	9.8	Hortal et al. (*22*)
12–23 m	28.6	28.6	28.6	Hortal et al. (*22*)
24–35 m	15.3	15.3	15.3	Hortal et al (*22*)
36–47 m	8.9	8.9	8.9	Hortal et al (*22*)
48–59 m	8.9	8.9	8.9	Hortal et al (*22*)

NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis; DALY = disability-adjusted life year; GBD = global burden of disease.

Table 2 Estimated vaccine coverage in the Islamic Republic of Iran used for the TRIVAC model

Variable	Estimate (%)	Scenario		Source/s
		High	Low	
Coverage of DTP1 by age in 2014 (proxy for PCV doses given with DTP1)				
3 m	97.2	NA	NA	MoHME
6 m	98.5	NA	NA	MoHME
9 m	98.9	NA	NA	MoHME
12 m	99.3	NA	NA	MoHME
24 m	100.0	NA	NA	MoHME
Coverage of DTP2 by age in 2014 (proxy for PCV doses given with DTP2)				
3 m	0.0	NA	NA	MoHME
6 m	98.3	NA	NA	MoHME
9 m	98.6	NA	NA	MoHME
12 m	99.1	NA	NA	MoHME
24 m	100.0	NA	NA	MoHME
Coverage of DTP3 by age in 2014 (proxy for PCV doses given with DTP3)				
3 m	0.0	NA	NA	MoHME
6 m	98.0	NA	NA	MoHME
9 m	98.5	NA	NA	MoHME
12 m	99.0	NA	NA	MoHME
24 m	100.0	NA	NA	MoHME

PCV = pneumococcal conjugate vaccine; DPT = diphtheria, tetanus, pertussis; NA = not applicable; MoHME = Ministry of Health and Medical Education, I.R. of Iran.

Table 3 Estimated vaccine efficacy used for the TRIVAC model to estimate the health impact of PCV-13

Variable	Estimate (%)	Scenario		Source/s
		High	Low	
Vaccine efficacy for all-cause acute otitis media				
Dose 1	28.9	48.4	25.3	Mahon et al. 2006 (24)
Dose 2	52.5	63.0	46.0	Mahon et al. 2006 (24)
Dose 3	57.0	63.0	50.0	Pavia et al. 2009 (24)
Vaccine efficacy for vaccine-type pneumococcal pneumonia/meningitis/NPNM				
Dose 1	41.0	69.2	31.9	Mahon et al. 2006 (24)
Dose 2	74.5	90.0	58.0	Mahon et al. 2006 (24)
Dose 3	81.0	90.0	63.0	Lucero et al. 2015 (2)
Vaccine serotype coverage				
Acute otitis media	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal pneumonia	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal meningitis	70.0	64.0	75.0	Johnson et al. 2010 (25)
Pneumococcal NPNM	70.0	64.0	75.0	Johnson et al. 2010 (25)
Other assumptions for vaccination impact				
Relative coverage	90.0	80.0	100.0	TRIVAC assumption (15)
Decrease in dose efficacy per year	5.0	0.0	10.0	TRIVAC assumption (15)
Contribution of herd effect in children < 5 years	110.0	100.0	120.0	TRIVAC assumption (15)
Decline in vaccine-type coverage per year	5.5	0.0	5.0	TRIVAC assumption (15)

PCV = pneumococcal conjugate vaccine; NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis.

Table 4 Data used for variables in the TRIVAC model to estimate programme costs of pneumococcal conjugate vaccine-13

Variable	Estimate	Scenario		Source/s
		High	Low	
Projected vaccine price per dose (US$)				
2014	20.00	35.00	14.24	Local representative of the manufacturer
2015	18.00	31.50	12.82	Derived from TRIVAC
2016	16.20	28.35	11.53	Derived from TRIVAC
2017	14.58	25.52	10.38	Derived from TRIVAC
2018	13.12	22.96	9.34	Derived from TRIVAC
2019	11.81	20.67	8.41	Derived from TRIVAC
2020	10.63	18.60	7.57	Derived from TRIVAC
2021	9.57	16.74	6.81	Derived from TRIVAC
2022	8.61	15.07	6.13	Derived from TRIVAC
2023	7.75	13.56	5.52	Derived from TRIVAC
Other vaccine dose costs				
International handling (% of vaccine price)	3.0	NA	NA	TRIVAC assumption (15)
International delivery (% of vaccine price)	2.0	NA	NA	TRIVAC assumption (15)
Wastage (e.g. % of doses discarded)	5.0	NA	NA	TRIVAC assumption (15)
Incremental system cost of introduction per dose (US$)	1.05	NA	NA	Calculated

NA = not applicable.

Health service utilization and costs

It was assumed that 95% of meningitis cases and non-pneumonia, non-meningitis cases are hospitalized based on data of the Iranian Ministry of Health and Medical Education. We asked five paediatricians to help with clinical assumptions; we assumed that 50% of pneumonia cases (that is, severe cases) need inpatient admission, and all non-severe pneumonia cases need outpatient services, similar to all cases of acute otitis media.

Two categories of public and private vaccination providers were considered: clinics and all types of hospital. Distribution between outpatient clinics and hospital admissions was based on the Iranian Ministry of Health and Medical Education as shown in Table 5. To calculate the distribution between the public and private sector, we used data from the Ministry of Health and Medical Education, which indicated that 32.3% and 67.7% of outpatient services were provided by the public and private sector respectively, as were 95% and 5% of inpatient services (National Institute of Health Research, Islamic Republic of Iran, 2015, personal communication).

To estimate the average inpatient service cost, we selected a random sample of 20 patients from each of three groups of patients (pneumonia, meningitis, and non-pneumonia, non-meningitis infections) from a public paediatric hospital and we extracted services and costs based on ICD-10-CM diagnostic codes (*28*). Direct medical costs were estimated as bed costs, medications, diagnostic tests, nursing care, consultations and other costs. We considered mean inpatient costs in a paediatric hospital for all types of hospital in the public sector. We did the same in one general private hospital to estimate the mean cost of inpatient admission in the private sector. Government costs per inpatient admission include mean cost per inpatient day multiplied by the expected length of stay that was covered by the universal public insurance system. Household costs per outpatient visit included direct medical costs (out-of-pocket payments for visit and medicines). Household costs per inpatient admission included out-of-pocket expenditure for direct medical costs of treatment of these diseases. Government costs per outpatient visit included the cost of visit, laboratory tests, X-rays and treatment. Government spending for admission is the daily costs for each inpatient case, which varies according to the type of disease.

For outpatient services, we estimated the pattern of prescribing, diagnostic tests and medications by interviewing 20 professors of paediatric infectious diseases, paediatricians and general physicians. We extracted costs separately for the public and private sector to estimate mean outpatient costs. We considered out-of-pocket payments as household expenditure and the costs covered by the universal public insurance system as government costs.

We estimated average inpatient and outpatient costs for household and government based on different tariffs and distribution of service utilization. All costs were converted from Iranian rials into US$ at a currency exchange rate of US$ 1.00 = 35 000 Iranian rials, which was an average of the official and market rates for 2014 (*29*).

Sensitivity analysis

We used upper and lower estimates for different inputs to calculate the incremental cost–effectiveness ratio in alternative scenarios.

Table 5 Data used for variables in the TRIVAC model to estimate health service utilization and costs (all costs are for 2014)

Variable	Estimate	Scenario		Source/s
		High	Low	
Outpatient visits				
Outpatient visits per disease episode				
All-cause acute otitis media	1	1	0.7	MoHME
Pneumococcal pneumonia	0.47	0.6	0.2	MoHME
Pneumococcal meningitis	0.05	0.08	0.02	MoHME
Pneumococcal NPNM	0.05	0.08	0.02	MoHME
Government cost per outpatient visit (US$)				
All-cause acute otitis media	2.6	3	2.2	Calculated
Pneumococcal pneumonia	7.4	8	6.8	Calculated
Pneumococcal meningitis	10.7	11.5	9.9	Calculated
Pneumococcal NPNM	15.4	16.2	14.6	Calculated
Household cost per outpatient visit (US$)				
All-cause acute otitis media	1.6	2	1.2	Calculated
Pneumococcal pneumonia	2.9	3.5	2.3	Calculated
Pneumococcal meningitis	4.6	5.4	3.8	Calculated
Pneumococcal NPNM	6.6	7.4	5.8	Calculated
Inpatient admissions				
Inpatient admissions per disease episode				
Pneumococcal pneumonia	0.47	0.6	0.2	MoHME
Pneumococcal meningitis	0.95	0.99	0.85	MoHME
Pneumococcal NPNM	0.95	0.99	0.85	MoHME
Government cost per inpatient admission (US$)				
Pneumococcal pneumonia	126.2	213.2	39.2	Calculated
Pneumococcal meningitis	434.4	461.4	427.4	Calculated
Pneumococcal NPNM	441.5	465.5	417.5	Calculated
Household cost per inpatient admission (US$)				
Pneumococcal pneumonia	117.2	204.2	30.2	Calculated
Pneumococcal meningitis	128.5	101.5	155.5	Calculated
Pneumococcal NPNM	100.2	124.2	76.2	Calculated
Meningitis sequelae				
Government cost of meningitis sequelae/year (US$)				
Major sequelae (single)	0	0	0	TRIVAC assumption (15)
Major sequelae (multiple)	0	0	0	TRIVAC assumption (15)
Household cost of meningitis sequelae/year (US$)				
Major sequelae (single)	4525.95	4073.35	4978.54	TRIVAC assumption (15)
Major sequelae (multiple)	4525.95	4073.35	4978.54	TRIVAC assumption (15)

NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis; MoHME = Ministry of Health and Medical Education, Islamic Republic of Iran.

Results

Estimated health benefits of pneumococcal conjugate vaccine-13

As shown in Table 6, the introduction of PCV-13 would avert 9998 deaths over the period 2014–2023, or 37.9% of all deaths from pneumococcal disease, and would prevent 105 802 inpatient admissions, 36.7% of all pneumococcal-related hospitalizations.

Estimated economic benefits

From a government perspective, PCV-13 was estimated to avert US$ 45.54 million discounted health service costs over the 10-year period, 2014–2023 (*Table 7*). From the perspective of society, the saving is about US$ 152.32 million.

The introduction of the PCV13 would be highly cost-effective with an incremental cost–effectiveness threshold of US$ 1890 and US$ 1538 per averted DALY

Table 6 Estimated health burden of pneumococcal diseases with and without PCV-13, and discounted health benefitsa of PCV-13 for 10 cohorts vaccinated over the period 2014–2023

Variable	No vaccine (current status)	PCV-13	Averted
Cases of pneumococcal disease in children < 5 years (no.)			
Total cases	**18 713 211**	**13 813 127**	**4 900 084**
All-cause acute otitis media	18 148 116	13 455 667	4 692 450
Pneumococcal pneumonia	519 412	328 563	190 849
Pneumococcal meningitis	6 884	4 354	2 529
Pneumococcal NPNM	38 799	24 543	14 256
Outpatient visits for pneumococcal disease in children < 5 years (no.)			
Total visits	**5 891 257**	**4 358 860**	**1 532 397**
All-cause acute otitis media	5 807 397	4 305 813	1 501 584
Pneumococcal pneumonia	83 106	52 570	30 536
Pneumococcal meningitis	114	72	42
Pneumococcal NPNM	640	405	235
Hospital admissions for pneumococcal disease in children < 5 years (no.)			
Total admissions	**287 950**	**182 147**	**105 802**
Pneumococcal pneumonia	246 721	156 067	90 653
Pneumococcal meningitis	6 213	3 930	2 283
Pneumococcal NPNM	35 016	22 150	12 866
Deaths from pneumococcal disease in children < 5 years (no.)			
Total deaths	**26 399**	**16 401**	**9 998**
Pneumococcal pneumonia	10 334	6 420	3 913
Pneumococcal meningitis	3 002	1 865	1 137
Pneumococcal NPNM	13 063	8 116	4 947
Children < 5 years with permanent disability (no.)			
Total disability	**958**	**615**	**343**
Sequelae group A	783	503	281
Sequelae group B	175	112	63
Burden of pneumococcal disease in children < 5 years			
Disability-adjusted life years	**804.12**	**500.77**	**303.34**
Years lived with disability	23.59	15.7	7.88
Years of life lost	780.53	485.07	295.46

PCV = pneumococcal conjugate vaccine; NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis.

[a]*Health benefits were discounted at 3% a year.*

from the perspective of the government and society, respectively. (*Table 8*).

Sensitivity analysis

In the sensitivity analysis, we ran 19 different scenarios in the model. As part of the analysis (Figure 1), two extreme scenarios were tested.

- The most favourable scenario included a low vaccine price, high incidence, high case fatality ratio, high vaccine efficacy, and high inpatient and outpatient treatment costs. With these conditions, vaccination was cost saving, which means it averted DALYs at a lower cost compared with the no vaccination.
- The least favourable scenario included a high vaccine price, low incidence, low case fatality ratio, low vaccine efficacy, and low inpatient and outpatient treatment costs: The incremental cost–effectiveness threshold was US$ 8857 per DALY averted (still cost-effective).

In all other scenarios, vaccination was highly cost-effective.

Discussion

Our results show that the introduction of PCV-13 would be a highly cost-effective intervention for the Iranian government and society when compared to no vaccination, based on WHO benchmarks for cost–effectiveness. The WHO Commission on Macroeconomics and Health has recommended that a discounted cost per DALY averted of less than the gross domestic product per capita should be considered highly cost-effective, and a discounted cost per

DALY averted of less than three times the gross domestic product per capita should be considered cost-effective (*30*).

We estimated that vaccination could prevent more than 4.5 million cases of pneumococcal-associated disease over the period 2014–2023. A national immunization programme with PCV-13 was estimated to prevent 38% of all deaths from pneumococcal diseases. The economic burden to society of pneumococcal diseases in children under 5 years in the Islamic Republic of Iran during 2014–2023 was calculated to be US$ 447.78 million; about 34% (US$ 152.32 million) of this cost could be prevented through vaccination. The cost to the government was estimated to be US$ 127.85 million, about 37% (US$ 45.54 million) of which could be prevented with PCV-13.

In developing countries, various studies have shown that PCV-13 is a cost-effective public health intervention. In Egypt, for 10 cohorts, the introduction of PCV-13 would be cost-effective, with an incremental cost–effectiveness ratio of US$ 3916 per DALY averted for the government. The total incremental cost of the PCV-13 vaccination programme would be about US$ 1.09 billion (*9*). In Peru, for 20 cohorts, net costs of PCV-10 and PCV-13 were estimated to be US$ 363.26 million and US$ 408.26 million respectively. DALYs averted were 226 370 with PCV-10 and 313 119 with PCV-13. The saving on treatment costs was estimated to be US$ 37.39 million with PCV-10 and US$ 47.22 million with PCV-13. Costs per DALY averted were US$ 1605 for PCV-10 and US$ 1304 for PCV-13. Therefore, the PCV-13 would be the preferred option (*6*). In Croatia, both PCV-10 and PCV-13 were estimated to prevent about 100 hospital admissions and one death each year in children under 5 years. Compared with no vaccine, the discounted cost–effectiveness of either vaccine was estimated to be about US$ 69 000–77 000 per DALY averted (19 cohorts) for the government or society. PCV-10 was more cost-effective than PCV-13, but this would be affected by the price of the vaccine (*31*).

There are some limitations to our study. First, data from the private sector were not easily available. Second, we did not include some important cost items which indirectly affect the population; for example, opportunity costs such as loss of productivity of parents when taking care of their sick children were not included. However, we believe that if we were to include these indirect cost, the incremental cost–effectiveness ratios would change in favour of vaccination. Finally, our results only took into

Table 7 Estimated costs of pneumococcal diseases with and without PCV-13, and discounted economic benefits[a] of PCV-13 for 10 cohorts vaccinated over the period 2014–2023

Variable	Estimated costs (US$)		
	No vaccine (current status)	PCV-13	Averted
Total government health service costs (× 1000)	**127 854**	**82 315**	**45 540**
Total outpatient visit costs	13 825	10 184	3 642
All-cause acute otitis media	13 212	9 796	3 416
Pneumococcal pneumonia	602	381	221
Pneumococcal meningitis	1.2	0.8	0.4
Pneumococcal NPNM	9 828	6 217	3 611
Total inpatient admissions	114 029	72 131	41 898
Pneumococcal pneumonia cases	77 717	49 161	28 556
Pneumococcal meningitis	5 393	3 411	1 981
Pneumococcal NPNM	30 920	19 559	11 361
Total society health service costs (× 1000)	**447 780**	**295 463**	**152 318**
Total outpatient visit costs	104 770	77 251	27 518
All-cause acute otitis media	100 831	74 760	26 071
Pneumococcal pneumonia	3 886	2 458	1 428
Pneumococcal meningitis	6.6	4.2	2.4
Pneumococcal NPNM	47	30	17
Total inpatient admissions	211 858	134 014	77 844
Pneumococcal pneumonia	163 537	103 448	60 089
Pneumococcal meningitis	7 503	4 746	2 757
Pneumococcal NPNM	40 818	25 820	14 998
Total sequelae costs	131 154	84 198	46 956
Major sequelae (single)	107 259	68 858	38 401
Major sequelae (multiple)	23 894	15 340	8 555

PCV = pneumococcal conjugate vaccine; NPNM = non-pneumonia, non-meningitis, and other diseases except sepsis.

[a]*Costs were discounted at 3% a year.*

Table 8 Discounted cost–effectiveness[a] of PCV-13 (10 cohorts vaccinated over the period 2014–2023) compared with no vaccination for the government and society

	Government	Society
Net cost of PCV-13 introduction (million US$)	573.31	466.53
Cost of vaccine introduction	618.85	618.85
Health service costs avoided	45.54	152.32
DALYs averted (000s)	303.34	303.34
Years lived with disability averted	7.88	7.88
Years of life lost averted	295.46	295.46
US$ per DALY averted	1 890	1 538
Cost–effectiveness threshold (US$)		
1 × GDP per capita (2012)b	4 526	4 526
3 × GDP per capita (2012)c	13 578	13 578

DALY = disability-adjusted life year; GDP = gross domestic product.

[a]*Costs and DALYs were discounted at 3% a year.*

[b]*World Health Organization threshold for highly cost-effective.*

[c]*World Health Organization threshold for cost-effective.*

Figure 1 Sensitivity analysis: cost-effectiveness of introducing pneumococcal conjugate vaccine-13 (government and society perspective) in different scenarios (GDP: gross domestic product)



account children under 5 years. Further analysis should therefore be done to estimate the economic and health burden of pneumococcal disease in older age groups.

Conclusion

Introduction of PCV-13 would be a high-impact public health intervention for the Islamic Republic of Iran and could prevent many cases of pneumococcal disease and 38% of all pneumococcal-related deaths. Evidence-based decision-making for the introduction of new vaccines guide the efficient use of resources in low- and middle-income countries. This study attempted to provide good scientific evidence that can inform decisions about the use of PCV-13 in the Islamic Republic of Iran.

Acknowledgments

We are grateful to the Iranian Ministry of Health and Medical Education, especially the Center for Communicable Disease Control, and the WHO country office in the Islamic Republic of Iran. We thank all advisers and colleagues, especially Gabriela Felix, for their technical support.

Funding: This work was supported by the ProVac International Working Group, which is funded entirely by a grant from the Bill & Melinda Gates Foundation (grant number: OPP1032888).

Competing interests: None declared.

Rapport coût-efficacité de l'introduction du vaccin antipneumococcique conjugué pour les enfants de moins de cinq ans en République islamique d'Iran

Résumé

Contexte : L'infection à pneumocoque causée par *Streptococcus pneumoniae* entraîne une mortalité et une morbidité considérables. Les vaccins antipneumococciques conjugués (VPC) comme le VPC-13 permettent de prévenir l'infection invasive à pneumocoque et d'éviter l'incapacité et les décès. Le coût de l'introduction du VPC-13 dans les calendriers de vaccination des enfants devrait être évalué par rapport au coût des infections à pneumocoque pour chaque communauté.

Objectifs : La présente étude visait à évaluer le rapport coût-efficacité de l'introduction du VPC-13 dans le programme national de vaccination des enfants de moins de cinq ans en République islamique d'Iran.

Méthodes : Le modèle TRIVAC pour le processus décisionnel en matière de la vaccination a été utilisé pour estimer le coût total de l'introduction du VPC-13 et les années de vie ajustées sur l'incapacité évitées. Les principales infections à pneumocoque – pneumonie, méningite, otite moyenne aiguë et infections autres que pneumonies et méningites – ont été prises en compte eu égard aux hospitalisations, consultations externes et décès. Des données locales ont été utilisées pour estimer les coûts.

Résultats : Selon les estimations, en l'absence de vaccination, l'infection à pneumocoque touchera 18 713 211 enfants de moins de 5 ans (519 412 cas de pneumonie, 18 148 116 cas d'otite moyenne aiguë, 6884 cas de méningite et 38 799 cas d'infections autres que pneumonies et méningites) sur une période de 10 ans (2014-2023). L'introduction du VPC-13 permettrait de prévenir 4 900 084 cas d'infection à pneumocoque (190 849 cas de pneumonie, 4 692 450 cas d'otite moyenne aiguë, 2529 cas de méningite et 14 256 cas d'infections autres que pneumonies et méningites). L'infection à pneumocoque entraînerait 287 950 hospitalisations et 29 399 décès. La vaccination permettrait d'éviter 105 802 hospitalisations et 9997 décès. Le rapport coût-efficacité cumulatif a été estimé à 1890 USD et 1538 USD par année de vie ajustée sur l'incapacité évitée pour le gouvernement et la société respectivement.

Conclusion : Selon les seuils recommandés par l'OMS pour interpréter le rapport coût-efficacité, l'introduction du VPC- 13, pour les enfants de moins de 5 ans en République islamique d'Iran, aurait un bon rapport coût-efficacité.

فعالية تكلفة إدخال لقاح المكورات الرئوية المتقارن للأطفال دون سن الخامسة في جمهورية إيران الإسلامية

خديجة إزوجي، محسن يعقوبي، مرضية نجومي، سوسن محمودي، سيد محسن–زهرائي، مازيار مرادي–لاكيه، صديقة طبطبائي، عبد الله كريمي

الخلاصة

الخلفية: يتسبب مرض المكورات الرئوية الناجم عن العقدية الرئوية في كثير من حالات الوفاة والمراضة. ويمكن الوقاية من مرض المكورات الرئوية الغزوي وتفادي الإعاقة والوفاة عن طريق لقاحات المكورات الرئوية المتقارنة، مثل لقاح PCV–١٣. كما أن تكلفة إدراج لقاح PCV–١٣ في جداول تحصين الأطفال والتي ينبغي تقييمها في ضوء تكلفة أمراض المكورات الرئوية التي يتكبدها كل مجتمع.

الأهداف: هدفت هذه الدراسة إلى تقييم فعالية تكلفة إدراج لقاح PCV–١٣ في برنامج التمنيع الوطني للأطفال دون سن ٥ سنوات في جمهورية إيران الإسلامية.

طرق البحث: استُخدم نموذج دعم القرارات المُسمى TRIVAC لتقدير إجمالي تكاليف إدخال لقاح PCV–١٣، وجُنِّبت سنوات العمر المُعدَّلة حسب الإعاقة (DALYs). ونُظر في أمراض المكورات الرئوية الرئيسية –الالتهاب الرئوي، والتهاب السحايا، والتهاب الأذن الوسطى الحاد، والعداوى غير الناجمة عن الالتهاب الرئوي أو التهاب السحايا– من حيث حالات الحجز في المستشفى وزيارات العيادات الخارجية والوفيات. واستُخدمت بيانات محلية لتقدير التكاليف.

النتائج: أشارت التقديرات إلى أن مرض المكورات الرئوية سيصيب ١٨٧١٣٢١١ طفلاً ممن تقل سنهم عن ٥ سنوات (الالتهاب الرئوي: ٥١٩٤١٢، والتهاب الأذن الوسطى الحاد: ١٨١٤٨١١٦، والتهاب السحايا: ٦٨٨٤، العداوى غير الناجمة عن الالتهاب الرئوي أو التهاب

السحايا: ٧٩٩ ٣٨) خلال ١٠ عشر سنوات (من ٢٠١٤ إلى ٢٠٢٣) من دون استخدام اللقاح. وأن استخدام اللقاح PCV–١٣ من شأنه أن يحول دون إصابة ٠٨٤ ٩٠٠ ٤ حالة بمرض المكورات الرئوية (الالتهاب الرئوي: ٨٤٩ ١٩٠، والتهاب الأذن الوسطى الحاد: ٤٥٠ ٦٩٢ ٤، والتهاب السحايا: ٢٥٢٩، والعداوى غير الناجمة عن الالتهاب الرئوي أو التهاب السحايا: ٢٥٦ ١٤). وسوف تتسبب عدوى المكورات الرئوية في دخول ٩٥٠ ٢٨٧ مريضاً المستشفى، وفي ٢٩ ٣٩٩ حالة وفاة. أما مع التطعيم، فيمكن تجنب ٨٠٢ ١٠٥ من حالات دخول المستشفى و٩٩٩٧ حالة وفاة. وقُدِّرت فعالية التكلفة الإضافية للحكومة وللمجتمع بمبلغ ١٨٩٠ دولاراً أمريكياً، و١٥٣٨ دولاراً أمريكياً لكل سنة مُجنَّبة من سنوات العمر المُعدَّلة حسب الإعاقة، على الترتيب.

الاستنتاج: وفقاً للحدود الدنيا التي أوصت بها منظمة الصحة العالمية لتفسير الفعالية من حيث التكلفة، سيكون إدخال لقاح PCV–١٣ للأطفال دون سن ٥ سنوات في جمهورية إيران الإسلامية فعالاً من حيث التكلفة.

References

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902.
2. Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RAN, Nohynek H, et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;(4):CD004977.
3. Ordóñez JE, Orozco JJ. Cost–effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia. BMC Infect Dis. 2014;14(1):172.
4. Wu DB-C, Chang C-J, Huang Y-C, Wen Y-W, Wu C-L, Fann CS-J. Cost–effectiveness analysis of pneumococcal conjugate vaccine in Taiwan: a transmission dynamic modeling approach. Value Health. 2012;15(1 Suppl):S15–S9.
5. González-Moro JMR, Menéndez R, Campins M, Lwoff N, Oyagüez I, Echave M, et al. Cost effectiveness of the 13-valent pneumococcal conjugate vaccination program in chronic obstructive pulmonary disease patients aged 50+ years in Spain. Clin Drug Investig. 2016;36(1):41–53.
6. Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, et al. Cost–effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine. 2015;33:A154–A66.
7. Constenla DO. Post-introduction economic evaluation of pneumococcal conjugate vaccination in Ecuador, Honduras, and Paraguay. Rev Panam Salud Publica. 2015;38(5):388–95.
8. Martí SG, Colantonio L, Bardach A, Galante J, Lopez A, Caporale J, et al. A cost–effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc. 2013;11(1):1.
9. Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, et al. Cost–effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine. 2015;33:A182–A191.
10. Caldwell R, Roberts CS, An Z, Chen C-I, Wang B. The health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) during an annual influenza epidemic and influenza pandemic in China. BMC Infect Dis. 2015;15(1):1.
11. Haasis MA, Ceria JA, Kulpeng W, Teerawattananon Y, Alejandria M. Do pneumococcal conjugate vaccines represent good value for money in a lower-middle income country? A cost-utility analysis in the Philippines. PloS One. 2015;10(7):e0131156.
12. Houri H, Karimi A, Saee Y, Fallah F, Rahbar M, Tabatabaei SR. Distribution of capsular types and drug resistance patterns of invasive pediatric Streptococcus pneumoniae isolates in Teheran, Iran. Int J Infect Dis. 2017;57:21–6.
13. World Health Organization. Global health estimates. 2015 (https://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html, accessed 14 March 2019.
14. Pooripussarakul S, Riewpaiboon A, Bishai D, Muangchana C, Tantivess S. What criteria do decision makers in Thailand use to set priorities for vaccine introduction? BMC Public Health. 2016;16(1):1.
15. Clark A, Jauregui B, Griffiths U, Janusz CB, Bolaños-Sierra B, Hajjeh R, et al. TRIVAC decision-support model for evaluating the cost-effectiveness of Haemophilus influenzae type b, pneumococcal and rotavirus vaccination. Vaccine. 2013;31:C19-C29.
16. Institute for Health Metrics and Evaluation (IHME). 2015 (http://www.healthdata.org/iran, accessed 31 March 2019).
17. United Nations. Population Division. World Population Prospects. Life expectancy at birth. 2012 (https://population.un.org/wpp/Download/Standard/Population/, accessed 31 March 2019).
18. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3(1):010401.
19. Edmond K, Clark A, Korczak VS, Sanderson C, Griffiths UK, Rudan I. Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(5):317–28.
20. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

21. Griffiths UK. Haemophilus influenzae type b vaccine in low- and middle-income countries: impact, costs and incremental cost-utility [PhD thesis].London: London School of Hygiene and Tropical Medicine; 2012. doi: https://doi.org/10.17037/PUBS.02869500

22. Hortal M, Estevan M, Iraola I, De Mucio B. A population-based assessment of the disease burden of consolidated pneumonia in hospitalized children under five years of age. Int J Infect Dis. 2007;11(3):273–7.

23. Pavia M, Bianco A, Nobile CG, Marinelli P, Angelillo IF. Efficacy of pneumococcal vaccination in children younger than 24 months: a meta-analysis. Pediatrics. 2009;123(6):e1103–e10.

24. Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI, et al. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24(14):2514–20.

25. Johnson HL, Deloria-Knoll M, Levine OS, Stoszek SK, Freimanis Hance L, Reithinger R, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10).

26. Tabatabaei SR, Fallah F, Shiva F, Shamshiri A, Hajia M, Navidinia M, et al. Multiplex PCR assay for detection of pneumococcal serotypes in nasopharyngeal samples of healthy children; Tehran, 2009-2010. Annu Res Rev Biol. 2014;4(24):3780–90.

27. Edejer T, Baltussen R, Adam T, Hutubessy R, Acharya A, Evans DB, et al., editors. Making choices in health: WHO guide to cost-effectiveness analysis. Geneva: World Health Organization; 2003 (https://apps.who.int/iris/bitstream/handle/10665/42699/9241546018.pdf?sequence=1, accessed 31 March 2019).

28. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130–9

29. Central Bank of the Islamic Republic of Iran. Exchange rate (https://www.cbi.ir/exrates/rates_fa.aspx, accessed 20 March 2019).

30. The World Health Report 2002: reducing risks, promoting healthy life. Geneva: World Health Organization; 2002.

31. Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark A, Mounaud B, et al. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vaccine. 2015;33:A209–A18.